Estrogen metabolites for lowering intraocular pressure

Details Estrogen metabolites for lowering intraocular pressure Estrogen metabolites for lowering intraocular pressure

1994-10-13

1996-05-28

Fay, Zohreh

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514170, 514913, A61K 3133, A61K 3156

Patent

active

055211682

ABSTRACT:
Methods for lowering and controlling intraocular pressure using estrogen metabolites are disclosed.

REFERENCES:
patent: 4876250 (1989-10-01), Clark
patent: 5371078 (1994-12-01), Clark et al.
Treister, et al., Intraocular Pressure and Outflow Facility, Arch. Ophthal., 83, 311-318 (Mar., 1970).
Meyer, et al., Influence of Norethynodrel With Mestranol on Intraocular Pressure in Glaucoma, Arch. Ophthal., 75, 771-773 (Jun., 1966).
Fotsis, et al., The Endogenous Oestrogen Metabolite 2-Methoxyestradiol Inhibits Angiogenesis and Suppresses Tumour Growth, Letters to Nature, 368, 237-239 (Mar. 17, 1994).

Affiliated with

Also associated with

Rating

Estrogen metabolites for lowering intraocular pressure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Estrogen metabolites for lowering intraocular pressure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estrogen metabolites for lowering intraocular pressure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-786862